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Abstract
Background: The incidence and prevalence of chronic kidney disease (CKD) continue to rise worldwide. Increasing
age, diabetes, hypertension, and cigarette smoking are well-recognized risk factors for CKD. Chronic obstructive
pulmonary disease (COPD) is characterized by chronic airway inflammation leading to airway obstruction and
parenchymal lung destruction. Due to some of the common pathogenic mechanisms, COPD has been associated
with increased prevalence of CKD.
Methods: Systematic review of medical literature reporting the incidence and prevalence of CKD in patients with
COPD using the Cochrane Collaboration Methodology, and conduct meta-analysis to study the cumulative effect of
the eligible studies. We searched Medline via Ovid, PubMed, EMBASE and ISI Web of Science databases from 1950
through May, 2016. We included prospective and retrospective observational studies that reported the prevalence
of CKD in patients with COPD.
Results: Our search resulted in 19 eligible studies of which 9 have been included in the meta-analysis. The
definition of CKD was uniform across all the studies included in analysis. COPD was found to be associated with
CKD in the included epidemiological studies conducted in many countries. Our meta-analysis showed that COPD
was found to be associated with a significantly increased prevalence of CKD (Odds Ratio [OR] = 2.20; 95%
Confidence Interval [CI] 1.83, 2.65). Study limitations: Studies included are observational studies. However, given the
nature of our research question there is no possibility to perform a randomized control trial.
Conclusions: Patients with COPD have increased odds of developing CKD. Future research should investigate the
pathophysiological mechanism behind this association, which may lead to better outcomes.
Keywords: Chronic obstructive pulmonary disease, Emphysema, Chronic bronchitis, Chronic kidney disease,
Comorbidity, Glomerular filtration rate
Background
Chronic kidney disease (CKD) is a major public health
problem in the United States, with rising incidence and
prevalence of kidney failure, with poor outcomes and high
cost. There is an even higher prevalence of earlier stages
of CKD. According to the Third National Health and
Nutrition Examination Survey (NHANES III), it was
estimated that 6.2 million people (3% of total US popula-
tion) above the age of 12 years had a serum creatinine
above 1.5 mg/dl and 8 million people had a glomerular
filtration rate (GFR) <60 ml/min/1.73 m2 The majority of
these people are greater than 65 years of age (5.9 million).
Diabetes, hypertension and cardiovascular disease are
associated with greater prevalence of CKD [1, 2]. In
addition, CKD has a complicated interrelationship with
these diseases. As per United States Renal Data System
(USRDS data), prevalence of stage 3 CKD has been
increasing. Although the prevalence of hypertension
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(HTN) did not rise, the incidence of diabetes mellitus
(DM) has increased 4 fold from 1980 to 2014 [3]. Stud-
ies have reported that CKD is an independent risk factor
for cardiovascular disease [4]. In recent years, additional
causes of CKD have been recognized such as unrecov-
ered acute kidney injury (AKI) [5, 6] and use of proton
pump inhibitors (PPIs) [7, 8], In this manuscript we
analyze the association of CKD with COPD using the
limited data available… Several studies have identified
COPD as part of a systemic inflammatory syndrome
[9–12] and reported on the association of comorbidities
like lung cancer [13], osteoporosis [14], progression of
atherosclerosis [15], and CKD. This systematic review was
performed to assess the association of COPD with CKD.
Methods
Eligibility criteria
We included prospective and retrospective observational
studies that reported the prevalence of CKD in patients
with COPD when compared to those without COPD.
Most of the studies established the diagnosis of COPD
using Spirometry or ICD-9 codes obtained from their
medical records while others were based on history or
physician diagnosed COPD. Prevalence of CKD in the
majority of the studies was reported based on eGFR
obtained from laboratory data. We only included studies
that reported data on adult populations.
Search strategy
In January 2016, we electronically searched PubMed,
Medline (1950 onwards; access via Ovid), EMBASE (all
years; access via Ovid) and Web of Science using a de-
tailed search strategy with search terms described below
and in Additional file 1. After initial detailed discussion
of the aim of the study, the search strategy was outlined
by the authors. Search terms used for COPD were:
‘COPD’, ‘chronic obstructive pulmonary disease’, ‘emphy-
sema’, ‘chronic bronchitis’. Search terms used for CKD
were: ‘chronic kidney disease’, ‘CKD’, ‘ESRD’, ‘end stage
renal disease’, ‘renal insufficiency’, ‘renal failure’.
Inclusion criteria: We included all prospective and
retrospective observational studies reporting the preva-
lence of CKD in patients with COPD compared to those
without COPD; there were no restrictions on language
of publication.
Exclusion criteria: We excluded studies that did not
report the association of CKD with COPD; those that
were not focused on the association of CKD with COPD;
studies that did not have appropriate methodological
study design of comparison groups; studies with data
which was incompletely recorded; and those involving
pediatric populations.
We reviewed keywords and related studies. From using
the selected studies, we proceeded further in the
literature search looking for “related articles” in
PubMed. References of the included studies were manu-
ally searched to ensure inclusion of all related articles.
Selection process
Two reviewers independently reviewed the titles and ab-
stracts of the citations resulting from the search using a
standardized screening guide. Full text was obtained for
the articles which were thought to be eligible by at least
one of the reviewers.. Each reviewer reviewed these full
texts independently to judge their eligibility to be in-
cluded in our review. Disparities between the two re-
viewers about which studies should be included were
discussed and resolved by a third reviewer.
Data abstraction
Data was independently extracted from the included studies
by two reviewers (SG and SGK) using a standardized and
pilot-tested form for data abstraction. Any differences in ex-
tracted data were discussed by the reviewers, and if not re-
solved, by discussion with a third reviewer. The pilot-tested
form included study design, method used to diagnose
COPD and CKD, population, methodological characteris-
tics of the study, and the reported results. We recorded the
effect measures derived from the regression models that ad-
justed for the maximum number of covariates. We rated
the overall quality of evidence for each outcome using the
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) approach [16].
Data analysis
The kappa statistic was calculated to determine the
agreement between the two reviewers of the full texts of
the studies for inclusion eligibility. Meta-analysis was
performed from the studies that reported the preva-
lence/incidence of CKD in patients with COPD com-
pared to patients without COPD. In studies that did not
report actual number of events, other available data
(such as percentages) was used to calculate the number
of events for the evaluated outcomes. For each outcome,
we pooled the odds ratios (OR) of eligible studies using
the generic inverse variance and the random effects
model in Review Manager Version 5.3. The random ef-
fects model was used as the included studies evaluated
different patient populations. We measured homogeneity
across study results using the I2 statistic. We examined
possible publication bias using inverted funnel plots.
Results
Our extensive electronic database search of databases in
January, 2016 resulted in 7583 articles. A flow diagram
with detailed outline of literature search is provided in
Additional file 2. After detailed review of the articles,
our literature search resulted in 17 studies related to the
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topic of our research. Manual search for related articles
helped identify an additional study that was recently
published and did not have a PubMed ID [17]. Another
study was published in April 2016 while we were in the
process of submission for publication [18]. As a result,
we included 19 articles related to our topic of interest.
Nine of these studies reported the prevalence of CKD
in patients with COPD compared to those without
COPD [17–26]. We reported a detailed review of these
studies with data extraction in Table 1 and we included
the results reported in these studies in a meta-analysis
to estimate the cumulative effect. The remaining 10
studies did not meet inclusion criteria for meta-analysis
[27–35]. A detailed review of these articles is reported in
Table 2. Eight of these 10 studies have been excluded
since they are longitudinal studies that reported the
prevalence of CKD in a cohort of patients with COPD
[18, 27–30, 32–34]. One of the studies has been ex-
cluded due to the study design and since the data could
not be used for analysis [31]. One other study was ex-
cluded due to use of non-standardized method to assess
the prevalence of CKD and therefore did not meet cri-
teria to be included in the systematic review [35]. The
reviewers had very good agreement on study eligibility
(kappa = 0.983). Using GRADE approach [16], the qual-
ity of evidence from the studies included in our review
was found to be moderate to low.
Results from meta-analysis (Fig. 1) showed statistically
significant higher prevalence of CKD among COPD
patients compared to controls without COPD; OR 2.20
[95% CI: 1.83, 2.65]. I2 value of 82% indicates minimal
heterogeneity among the studies included in the analysis.
Funnel plot of the included studies revealed lack of pub-
lication bias (Fig. 2).
The study periods of almost all the studies were in
the last 2 decades except one study [30]. Three of the
9 studies included in meta-analysis utilized nationally
representative samples in their respective countries
[22, 24, 25]. Only 2 studies reported data on hospital-
ized patients [19, 26] while the remaining 4 studies
included patients from outpatient settings [17, 20, 21, 23].
Of the 10 studies that were excluded from the meta-
analysis, six studies reported data on hospitalized patients
[18, 27–30, 34]
Patient population included was aged 40 years or older.
Studies included in the meta-analysis had similar gender
representation with male participant rates reported from
40% to 65% except one study that reported 83% male
participation [17]. Nine of the 10 studies that were not in-
cluded in the meta-analysis but were included in the sys-
tematic review reported predominant male participation
ranging from 80% to 98% [18, 27–34].
Of the studies included in meta-analysis, only one
study analyzed prevalence of CKD in COPD and control
groups based on gender [24]. Van Gestel et al. analyzed
the association between prevalence of CKD and severity
of COPD [26]. Therefore sub-group analysis could not
be performed for prevalence based on gender and sever-
ity of COPD.
The reported diagnostic methods and definitions for
COPD and CKD were uniform across all the included
studies. The value of eGFR reported under laboratory data
was used to define CKD in most of these studies. Match-
ing was performed in control group selection in 3 of the 9
studies included in the meta-analysis [19, 21, 23]. All the
included studies performed adjustment in analysis for the
identified confounding variables.
Discussion
Our meta-analysis validated previously published results
showing a significant increase in prevalence of CKD in
patients with COPD compared to patients without
COPD. To our knowledge, this is the first meta-analysis
conducted on this topic.
Advancing age, diabetes, hypertension, body mass
index (BMI), and cigarette smoking have previously been
identified as risk factors for new-onset kidney disease
[36]. Advancing age, history of asthma, severe respira-
tory problems in childhood, passive smoking, and expos-
ure to biomass fuel for heating were identified as risk
factors for COPD in never-smokers whereas increasing
age, history of asthma, and severe respiratory problems
in childhood, increasing lifetime exposure to cigarette
smoking were identified as independent risk factors for
development of COPD in ever-smokers [37]. Many stud-
ies have reported on the high prevalence of CKD in
COPD patients across different populations and our
meta-analysis validated these previously published re-
sults. Moreover, all the studies included in our analysis
adjusted for co-variates including age, gender, BMI, and
smoking status and this allowed for drawing a conclu-
sion on the independent association of CKD with
COPD.
The mechanism by which COPD potentiates the de-
velopment of CKD remains unclear. Several hypotheses
have been put forward. It might be related to the fact
that COPD is mainly a disease of the elderly population
who have comorbidities such as DM, HTN and CAD,
known risk factors associated with CKD. COPD has
been associated with systemic inflammation [9–12]. Pro-
inflammatory cytokines, especially tumor necrosis
factor-alpha (TNF-α), play an important role in inflam-
mation [38, 39], and have been shown to increase
endothelial inflammation and atherosclerosis. This in-
flammation is also potentially related to development of
diabetes, muscle wasting, and kidney disease. In a
meta-analysis of observational studies, COPD was asso-
ciated with increased serum concentration of several
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Table 1 Systematic review of 9 studies reporting prevalence of CKD in patients with COPD compared to controls; included in meta-analysis
Study Population COPD diagnosis method & Definition
of CKD
Methodological features Results
Baty et al.; 2013 [8]
Study design: Population based
case-control study
Funding: Takeda Pharma AG,
Switzerland
Setting & period: All hospitalizations in
Switzerland between 2002 and 2010
COPD group: 340, 948 patients, 64%
males, median age 73 years
Non-COPD group: 340,948 patients,
64% males, median age 73 years
Diagnosis of COPD: Based on ICD-10
codes
CKD definition: Based on ICD-10
code







Confounding: no Matching: yes.
Adjustment in analysis: yes
Confounding variables: no
Loss to follow up: none
4.39% of patients with COPD had
Chronic kidney disease (ICD 10 code,
N188) compared to 2.13% of patients
without COPD (p < 0.001)
4.64% of patients with COPD had
Chronic kidney disease unspecified (ICD
10 code, N189) compared to 2.25% of
patients without COPD (p< 0.001)
Gjerde et al.; 2011 [9]
Study design: Case-control study
Funding: The Foundation for
Respiratory Research, Center for
Clinical Research, Bergen
Setting & period: Patients aged 40-76
years with COPD were recruited from
health institutions in Hordaland County
in Western Norway, where as those
without COPD were recruited among
former participants from a general
population survey in Hordaland County;
between 2006 and 2007
COPD group: 433 patients, 59.6% male
Non-COPD group: 233 patients
Diagnosis of COPD: using Spirometry
CKD definition: eGFR <60
Blinding of outcome adjudicator: not
reported






Confounding: yes Matching: no.
Adjustment in analysis: yes
Confounding variables: no
Loss to follow up: none
Prevalence of undiagnosed renal
failure in the COPD patients was
6.9%, significantly higher than
among the subjects without COPD
(p < 0.001)
Incalzi et al.; 2010 [10]
Study design: Case-control study
Funding: not reported
Setting & period: Participants aged
65 years and older were recruited from
pulmonary medicine outpatient facilities
in University of Palermo, Italy
COPD group: 356 patients
Non-COPD group: 290 patients
Diagnosis of COPD: Spirometry
CKD definition: eGFR < 60 using
MDRD equation







Confounding: no Matching: yes (age)
Adjustment in analysis: yes
Confounding variables: no
Loss to follow up: none
Overall prevalence of Chronic renal
failure was 43.0% in COPD group
and 23.4% in non-COPD group
(p < 0.001)
Logistic regression analysis revealed
significant association between COPD
and concealed chronic renal failure (OR:
2.19; CI: 1.17-4.12) and overt chronic
renal failure (OR: 1.94; CI: 1.01-4.66)
Joo et al.; 2012 [11]
Study design: Cross-sectional Survey
Funding: Grant of Korea Healthcare
Technology R&D project
Setting & period: Database of the fourth
Korean Health and Nutrition
Examination Survey with a nationally
representative sample, during 2008.
Aged ≥ 40 years
COPD group: 354 patients, 67.2% male,
mean age 64.6 years
Non-COPD group: 1823 patients, 36.9%
male, mean age 54.4 years
Diagnosis of COPD: Spirometry,
FEV1/FVC < 0.7
CKD definition: patients’ awareness
of CKD diagnosis was surveyed








Confounding: yes Matching: no.
Adjustment in analysis: yes Confounding
variables: gender, mean age
Loss to follow up: none
0.6% of patients in COPD group had
Chronic renal failure compared to
0.4% in non-COPD group (p = 0.41,
not statistically significant)
Mapel et al.; 2013 [12]
Study design: retrospective case-
control cohort analysis
Funding: grant from Pfizer
Pharmaceuticals Inc.
Setting & period: patients aged 40 years
or older seen in 4 hospitals and a
network of outpatient clinics of Lovelace
Health Systems (LHS) in New Mexico,
USA during the study period 2005-2008
COPD group: 2284 patients of LHS aged 40
or more with COPD and have at least 2
outpatient clinic visits or one hospitalization
and enrolled with LHS for at least
Diagnosis of COPD: ICD-9 diagnosis
code of COPD
CKD definition: ICD-9 codes and ab-
normal renal function tests







Confounding: no Matching: yes (age,
gender). Adjustment in analysis: yes
Confounding variables: no
Loss to follow up: none
Chronic renal failure was more than
three times more prevalent among
COPD patients (2.89%) than among















Table 1 Systematic review of 9 studies reporting prevalence of CKD in patients with COPD compared to controls; included in meta-analysis (Continued)
12 months during the study period;
47.5% men; mean age 70.3 +/- 9.8 yrs
Non-COPD group: 5959 randomly
selected patients without a diagnosis of
COPD and be of same age and gender
Nagorni-Obradovic; 2014 [13]
Study design: cross sectional study
(case-control analysis)
Funding: Ministry of Education and
Science of the Republic of Serbia
Setting & period: 10,013 nationally
representative sample of adults aged
40 years or older who participated in
multipurpose health survey of
population of Serbia in 2006
COPD group: 653 patients, 46.6% male,
mean age 62.8 years (SD: 12.4)
Non-COPD group: 9.360 patients, 54.4%
male, mean age 59.3 years (SD: 12.2)
Diagnosis of COPD: Self-reported
history of chronic bronchitis and
emphysema
CKD definition: Self-reported history
of chronic renal disease






Confounding: no Matching: no
Adjustment in analysis: yes (age, gender,
educational level, smoking) Confounding
variables: no
Loss to follow up: n/a
20.6% of COPD patients reported
having a diagnosis of chronic renal
failure compared to 9.3% of non-
COPD patients (p < 0.01)
Schnell et al., 2012 [14]
Study design: cross-sectional study
(case-control analysis)
Funding: Johns Hopkins, NCRR and
NIH
Setting & period: non-institutionalized
civilians in the US aged 45 years or more
who participated in the National Health
and Nutrition Examination Survey
(NHANES) from 1998 through 2008
COPD group: 995 patients, 39.9% males,
mean age 62.7 years
(CI: 61.7-63.8)
Non-COPD group: 14,828 patients, 47%
males, mean age 60 years (CI: 59.6-60.3)
Diagnosis of COPD: positive response
in NHANES questions to either
chronic bronchitis or emphysema
with negative response to current
asthma
CKD definition: NHANES question
with positive response to eGFR < 60
as calculated using MDRD equation






Confounding: no Matching: no
Adjustment in analysis: yes
Confounding variables: none
Loss to follow up: n/a
16.2% of patients with physician
diagnosed COPD reported having
low eGFR, compared to 10.5% of
patients without physician
diagnosed COPD (p < 0.0001)
Van Gestel et al.; 2009 [15]
Study design: cohort study
Funding: none
Setting & period: 3358 patients who
underwent elective vascular surgery or
lower limb arterial reconstruction
surgeries between January 1990 to
December 2006
COPD group: 1310 patients
Non-COPD group: 2048 patients
Diagnosis of COPD: post
bronchodilator pulmonary function
test
CKD definition: based on calculated
eGFR <60 estimated using MDRD
equation
Blinding of outcome adjudicator: not
reported





Confounding: yes. Matching: No.
Adjustment in analysis: yes
Confounding variables: age, gender,
type of surgery, current smoking,
previous heart failure, hypertension,
Diabetes, hyperlipidemia
Loss to follow up: none
COPD was associated with a higher
risk of prevalent CKD even after
adjustment for confounding
variables – OR: 1.22 (1.03 – 1.44)
(p = 0.03)
A borderline significant relationship
was observed for mild COPD while
moderate COPD was independently
associated with CKD. No significant
association was found between
severe COPD and CKD
Yoshizawa et al.; 2015 [6]
Study design: retrospective case-
control cohort analysis
Funding: none
Setting & period: outpatient clinic visits
of Kanamecho Hospital, Tokyo, Japan
for the study period of May 2011 to
April 2012
COPD group: 108 stable COPD patients;
83.3% males; mean age 74.3 ± 7.1 year.
Non-COPD group: 73 patients of the
same outpatient practice; 49.3% males;
mean age 71.8 ± 7.3 years
Diagnosis of COPD: spirometry reading
of FEV1/FVC less than 70% after
inhalation of a bronchodilator, and
severity of obstruction judged according
to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria
CKD definition: eGFR less than
60 mL/min/1.73 m2 as per calculation
based on serum Creatinine and serum
Cystatin levels separately







Confounding: yes. Matching: No.
Adjustment in analysis: yes
Confounding variables: age, gender,
BMI, hypertension, Diabetes,
hyperlipidemia
Loss to follow up: none
Prevalence of CKD (using Se Cr for
calculation of eGFR) was significantly
higher in COPD group - OR: 4.91 (1.94
– 12.46) (p = 0.0004)
Prevalence of CKD (using Se Cys for
calculation of eGFR) was significantly
higher in COPD group - OR: 6.30















Table 2 Systematic review of 10 studies reporting prevalence of CKD in patients with COPD; excluded from meta-analysis
Study Population COPD diagnosis method & Definition
of CKD
Methodological features Results
Almagro et al., 2002 [17]
Study design: prospective cohort
study
Funding: not reported
Setting & period: patients hospitalized
to an acute-care hospital in Barcelona
(Spain) for acute exacerbation of COPD,
between October 1996 and May 1997
Patient group: 135 patients, 96%
male, median age 72.2 ± 9.25 years
Diagnosis of COPD: Spirometry
CKD definition: not defined,
diagnosis information obtained from
Charlson index
Selection bias: yes, patients admitted
with COPD exacerbation
Information bias:
Objective outcome evaluation: no;
standardized CKD risk measurement: no
4.4% of the patients are reported to
have renal failure
Almagro et al., 2009 [18]
Study design: Cross-sectional, multi-
center study
Funding:
Setting & period: patients admitted
with COPD exacerbation to any of
the participating 26 hospital centers
throughout Spain, consecutively
between January 1, 2007 and
December 31, 2008
Patient group: 398 patients, 89%
male, mean age of 73.7 years
Diagnosis of COPD: Spirometry
CKD definition: not defined,
comorbidity information obtained
from Charlson index and an ad hoc
questionnaire
Selection bias: patients admitted with
COPD exacerbation
Information bias:
Objective outcome evaluation: no;
standardized CKD risk measurement: no
6.5% of patients are reported to have
moderate kidney failure
Almagro et al.; 2012 [16]
Study design: Longitudinal,
observational, multi-center study
Funding: provided by Chiesi España
Setting & period: Patients
hospitalized for COPD exacerbation
to 70 ED and internal medicine
services in Spain between October
2009 and October 2010
Patient group: 606 patients, 89.9%
male, median age 72.6 years (range,
41-94)
Diagnosis of COPD: Spirometry
CKD definition: not defined,
diagnosis information obtained
using Charlson index and a
questionnaire
Selection bias: yes, patients admitted
with COPD exacerbation
Information bias:
Objective outcome evaluation: no;
standardized CKD risk measurement:
no
15.5% of patients are reported
to have Kidney disease with serum
creatinine <3
0.7% of patients are reported to have
Kidney disease with serum creatinine
>3
Antonelli Incalzi et al., 1997 [19]
Study design: Retrospective cohort
study
Funding: not reported
Setting & period: Consecutive
patients discharged from Catholic
University in Rome between the
years 1980 and 1990, after an acute
exacerbation of COPD
Patient group: 270 patients, 83%
male, mean age 67 ± 9 (SD) years
Diagnosis of COPD: Spirometry
CKD definition: not defined, obtained
from Charlson’s index
Selection bias: patients likely with
severe COPD
Information bias:
Objective outcome evaluation: no;
standardized CKD risk measurement:
no
6.6% of patients were noted to have
chronic renal failure
Death in these patients was predicted
by several variables including chronic
renal failure
(HR 1.79; 95% CI 1.05–3.02)
Chen et al.; 2016 [7]
Study design: Case-Cohort study
Funding: Ministry of Science of
Technology, Taiwan
Setting & period: Patients aged
40 years or older who had inpatient
hospitalization between 1998 and
2008 with Longitudinal Health
Insurance Database
(LHID) 2000 as the case group
COPD group: 7,739 patients, 67.5%
males, mean age 71.7 years
Non-COPD group: 15,478 patients,
67.5% males, mean age 71.7 years
Diagnosis of COPD: Based on
hospitalization for COPD
CKD definition: Clinical diagnosis







Confounding: no Matching: yes.
Adjustment in analysis: yes
Confounding variables: yes; age,
gender, first diagnosis of COPD
Loss to follow up: none
Overall incidence of CKD was higher
in COPD group than in non-COPD
group. The adjusted hazard ratio of
case was 1.61 (P <0.0001) times that of
control.
Ford, E S.; 2015 [20]
Study design: retrospective case-
control study
Funding: None
Setting & period: 5711 American
men and women aged 40 to
79 years who participated in the
Third National Health and Nutrition
Examination Survey (NHANES III)
during the term 1988 through 1994
and followed through 2006
COPD group: 1390 participants
Diagnosis of COPD: spirometry
CKD definition: eGFR calculation
using the Chronic Kidney Disease
Epidemiology Collaboration
equations







Confounding: no Matching: yes.
Adjustment in analysis: yes
Confounding variables: no
The rates of incidence or prevalence
of CKD was not reported.
Comparative data on mean eGFR
values in COPD group and Non-COPD
group was reported.
Adjusted mean levels of eGFR were
significantly lower in adults with moderate-















Table 2 Systematic review of 10 studies reporting prevalence of CKD in patients with COPD; excluded from meta-analysis (Continued)
Non-COPD group: 4321 participants Loss to follow up: none in adults with normal lung function
(89.6 mL/min/1.73 m2) (p=0.015)
García-Olmos et al., 2013 [21]
Study design: Observational, cross-
sectional study
Funding: CDTI/Ministry of Science
and Innovation
Setting & period: practice population
allocated to 129 Family Physicians,
conducted in a health area of the
Madrid
Patient group: 3,183 patients, 76%
male, mean age of 71.41 ±
11.50 years
Diagnosis of COPD: from clinical
history in EMR
CKD definition: not defined, obtained
from EMR
Selection bias: not validated COPD
diagnostic method
Information bias:
Objective outcome evaluation: no;
standardized CKD risk measurement:
no
6.34% of patients have chronic renal
failure
Marti et al., 2005 [22]
Study design: Retrospective cohort
study
Funding: In part by grant from
Fundacio ‘noma’Catalana de
Pneumologia and by Red Respira-
ISCIII-RTIC-03/11
Setting & period: patients with COPD
initiating LTOT >15 h/day during
1992–1999 in a tertiary teaching
hospital (Vall d’Hebron Hospital,
Barcelona, Spain)
Patient group: 128 patients, 98.4%
male, mean age ± SD 68.9 ± 9.7 years
Diagnosis of COPD: PFTs
CKD definition: not defined, assessed
using Charlson index
Selection bias: yes, COPD patients only
on long term O2 therapy
Information bias:
Objective outcome evaluation: no;
standardized CKD risk measurement:
no
1.6% of patients are reported to have
renal disease




Setting & period: Consecutive COPD
patients admitted to four hospitals in
Italy for acute exacerbation from
1999 to 2000, and followed up until
December 2007
Patient group: 288 patients, 78.8%
male, mean age 69.2 years (SD ± 6.4)
Diagnosis of COPD: standardized
CKD definition: not defined, assessed
using Charlson index
Selection bias: yes, patients admitted
for acute exacerbation
Information bias:
Objective outcome evaluation: no;
standardized CKD risk measurement:
no
26.3% of patients are reported to
have chronic renal failure
Van Manen et al.; 2001 [24]
Study design: case control study
Funding: Boehringer Ingelheim NL
supplied materials and personnel for
performing lung function testing
Setting & period: Adults aged
40 years or more who visited
outpatient practices in urban and
suburban regions of western part of
Netherlands from October 1996
through June 1997
COPD group: 290 patients (male
64.1%; mean age 65.8 years)
Non-COPD group: 421 patients (male
41.1%; mean age 65.9 years)
Diagnosis of COPD: Pulmonary
function tests
CKD definition: not reported







Confounding: no Matching: no
Adjustment in analysis: yes
Confounding variables: no
Loss to follow up: none
The study population was surveyed to
estimate the prevalence of a set of 23
diseases in patients with COPD
compared to patients without COPD.
Self-reported renal disease was
included in general and no
specifications on chronic kidney
disease or renal failure was surveyed.
Renal disease was reported 0.3% in
patients with COPD compared to















inflammatory mediators [40]. This association can be
explained in part by smoking.
COPD is associated with microalbuminuria and in hyp-
oxemic and hypercapnic patients effective renal flow was
found to be reduced. These changes may be reflective of
increased renin-angiotensin system activity seen in COPD
patients. In the Multi-Ethnic Study of Atherosclerosis co-
hort, Harris et al. found an inverse relation between FEV1
and FVC with urinary albumin excretion and urine albu-
min to urine creatinine ratio [41]. This finding suggests
that systemic microvascular injury may contribute to
development of CKD in COPD patients.
Medical management of COPD may contribute to the
development of CKD. Mapel et al. [23] showed that
COPD patients were more likely to be on potentially
nephrotoxic medications than controls. This includes re-
current use of antibiotics, as well as PPIs and certain
cardiovascular drugs. Our study highlights the high
prevalence of CKD in COPD patients and draws atten-
tion to the clinical implications.
Our study has a few limitations. First and foremost,
we included observational studies in this systematic re-
view and meta-analysis. Observational studies, inher-
ently, depict associations and aid in hypothesis-making
but do not establish cause and effect relationships.
Additionally, we could not perform subgroup analysis to
estimate the differential prevalence of CKD in relation
to the severity of COPD that would have otherwise con-
tributed to establishing causal relationship. Another
limitation is that although 18 studies were identified to
be relevant, only 9 studies could be included in our
meta-analysis owing to differences in the study designs
and reported results. However, funnel plot analysis did
not reveal any publication bias.
Fig. 2 Funnel plot to assess for publication bias among the studies included in meta-analysis
Fig. 1 Meta- analysis to assess the cumulative prevalence of CKD in patients with COPD when compared to control groups
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Conclusions
In conclusion, results from our systematic review and
meta-analysis strongly support the association of increased
prevalence of CKD in patients with COPD. Implications
for future research include a need for studies to further
investigate the pathophysiological mechanisms in COPD
patients that lead to a higher incidence of CKD in these
patients. Results from these studies may then be applied
to improve the treatment of COPD, reducing the
incidence of CKD in COPD patients and thereafter
decrease their morbidity and mortality.
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